A regulatory framework developed by Nigerian pharmacist Ogechukwu Blessing Momah to improve the speed of pharmaceutical product approvals has received recognition from government agencies and industry stakeholders.

The framework, which some experts have dubbed the Momah Model, was created during her advisory work with Swissgarde and Ascendis Health. It introduces measures such as harmonising documentation, establishing predictive timelines, and working with embassy authentication units to minimise delays in pre-market approvals.

Industry data show that between 2020 and 2022, the model contributed to reducing inspection delays by more than half. It was also applied during Good Manufacturing Practice (GMP) inspections ahead of the rollout of several foreign-manufactured products into Nigeria.

According to the Deputy Director of Pharmaceutical Inspection at the National Agency for Food and Drug Administration and Control (NAFDAC), the model has provided practical benefits. “It provides clarity and removes bottlenecks for both the regulator and the manufacturer,” the official said, adding that it has improved efficiency, documentation quality, and compliance outcomes.

Beyond clearance processes, Momah has supported the training of regulatory officers on evaluating foreign labelling practices and ensuring product claims align with Nigerian standards. Her methods are now being adopted informally by a consortium of professionals working in inspections, dossier preparation, and post-market surveillance.

Policy analysts suggest that the approach is influencing conversations on possible revisions to NAFDAC guidelines governing imported finished products and herbal formulations. If implemented, the reforms could expand opportunities for small and mid-sized pharmaceutical firms seeking to enter the Nigerian market.